Global Search

Hide Filters

Showing 2972 results

Press release / Jan 24, 2023

Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio

Sandoz plans to acquire worldwide product rights for Mycamine® (micafungin sodium) from AstellasAcquiring leading global echinocandin, one of three major antifungal classes, will significantly…
Press release / Dec 13, 2022

Novartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5

Trial met both primary and most secondary endpoints, showing iptacopan provided transfusion-free hemoglobin-level increases in vast majority of adult paroxysmal nocturnal hemoglobinuria (PNH)…
Press release / Dec 13, 2022

Novartis receives European Commission approval for Pluvicto® as the first targeted radioligand therapy for treatment of progressive PSMA–positive metastatic castration-resistant prostate cancer

EC approval based on results from pivotal Phase III VISION trial, in which Pluvicto® plus best standard of care (BSoC) significantly improved overall survival and radiographic progression-free…
Press release / Dec 08, 2022

Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNH

Phase III APPOINT-PNH study of investigational oral monotherapy iptacopan met its primary endpoint; second positive Phase III topline readout for iptacopan in paroxysmal nocturnal hemoglobinuria (PNH…
Press release / Mar 31, 2023

Novartis Entresto receives positive CHMP opinion for pediatric heart failure

If subsequently approved, Entresto will be the first and only approved therapy for the treatment of symptomatic chronic heart failure patients aged 1 to <18 years in the European Union Pediatric…
Press release / Apr 03, 2023

Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation

Biosimilar Hyrimoz® (adalimumab) citrate-free high-concentration formulation (HCF) is now approved in the EU for use in all indications of reference medicine Humira®*HCF formulation adalimumab offers…
Press release / Apr 20, 2023

Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis

The ALITHIOS open-label extension study showed continuous treatment with Kesimpta® (ofatumumab) for up to five years in relapsing multiple sclerosis (RMS) patients was associated with reduced risk of…
Ad hoc release / Apr 25, 2023

Novartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance

Ad hoc announcement pursuant to Art. 53 LR Q1 sales grew +8% (cc1, +3% USD) and core operating income grew +15% (cc, +8% USD) Innovative Medicines (IM) sales grew +7% (cc, +3% USD) and core…
Ad hoc release / Apr 25, 2023

Novartis réalise une croissance forte de son chiffre d’affaires, une expansion robuste de sa marge, des étapes majeures de l’innovation et rehausse ses prévisions pour l’exercice 2023

Annonce événementielle au sens de l’art. 53 RC Au T1, chiffre d’affaires en hausse de +8% (tcc1, +3% USD) et du résultat opérationnel de +15% (tcc, +8% USD) Innovative Medicines (IM): hausse de +…
Ad hoc release / Apr 25, 2023

Novartis erzielt kräftige Umsatzsteigerungen, eine robuste Margenerhöhung und wichtige Innovationsmeilensteine. Erhöhung der Jahresprognose

Ad-hoc-Mitteilung gemäss Art. 53 KR Der Umsatz wuchs im ersten Quartal um +8% (kWk1, +3% USD), und das operative Kernergebnis verbesserte sich um +15% (kWk, +8% USD) Innovative…